AbbVie Inc Announces Positive Results from TEMPLE Study

AbbVie Inc, a biotechnology company specializing in pharmaceutical products, has announced positive topline results from its Phase 3 TEMPLE study. The study evaluated the efficacy and safety of atogepant, a daily oral migraine prevention drug, compared to topiramate.

Study Details

• The TEMPLE study was a Phase 3 clinical trial designed to assess the efficacy and safety of atogepant in reducing migraine frequency.
• The study compared atogepant to topiramate, a commonly used migraine prevention medication.
• The trial enrolled patients with episodic migraine and evaluated the treatments over a 12-week period.

Key Findings

• Atogepant met the primary endpoint, demonstrating superiority over topiramate in reducing treatment discontinuations due to adverse events.
• Atogepant achieved significant efficacy in reducing monthly migraine days, outperforming topiramate in all secondary endpoints.
• The study results suggest that atogepant may offer a new treatment option for patients suffering from migraines.

Next Steps

AbbVie Inc will continue to analyze the study data and prepare for regulatory submissions. The company aims to bring atogepant to market as a new treatment option for patients with migraines.